(Q39775306)

14 September 2017

title

Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls (English)

1 reference

14 September 2017

0 references

Brian Leyland-Jones

1

1 reference

14 September 2017

Brian R Smith

series ordinal

2

1 reference

14 September 2017

publication date

1 March 2011

1 reference

Lancet Oncology Commission

14 September 2017

published in

1 reference

14 September 2017

volume

12

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

286-295

1 reference

Biochemistry of HER2 oncogenesis in breast cancer.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast can

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Serum HER-2 concentration in patients with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

C-erbB-2 protein in the sera of breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Prognostic significance of serum c-erbB-2 protein in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970297-7

7 January 2021

10.1016/S1470-2045(10)70297-7

Identifiers

DOI

1 reference

14 September 2017

1 reference